Latest Information Update: 08 Dec 1997
At a glance
- Originator Novartis
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 08 Dec 1997 Discontinued-Preclinical for Diabetes mellitus in USA (Unknown route)
- 29 Sep 1997 New profile